Kathryn C. Zoon - 25 May 2023 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)

Role
Director
Signature
/s/ Jennifer Lynne Fox, Attorney-in-fact
Issuer symbol
EBS
Transactions as of
25 May 2023
Net transactions value
-$29,526
Form type
4
Filing time
24 Jul 2023, 08:28:36 UTC
Previous filing
13 Jun 2022
Next filing
23 May 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EBS Common Stock Sale $14,246 -1,700 -3.2% $8.38 51,801 25 May 2023 Direct F1
transaction EBS Common Stock Sale $15,280 -1,830 -3.5% $8.35 49,971 02 Jun 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Ms. Zoon.

Remarks:

This Form 4 was filed late due to an inadvertent administrative error. The Company will report all late Form 4s in it's next proxy statement.